Positive Emission Tomography for Evaluating a Complete Clinical Response in Patients with Ovarian or Peritoneal Carcinoma: Correlation with Second-Look Laparotomy

Rose, Peter G.; Faulhaber, Peter; Miraldi, Floro; Abdul‐Karim, Fadi W.

doi:10.1006/gyno.2001.6246

Cited by 122 publications

(52 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Size limitations in performing PET scans must be noted, since implants <10 mm are inconsistently identified owing to low concentrations and limited spacial resolution. [19] Miliary peritoneal dissemination was significantly associated with TFI<12 months and ascites at cytoreduction. Consequently, even if a PET scan indicates localized FDG uptake, we should carefully consider performing cytoreductive surgery for patients with TFI<12…”

Section: Discussionmentioning

confidence: 93%

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

Ebina

Watari

Kaneuchi

et al. 2013

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose. To investigate the impact of PET and PET-CT scanning on decision-making in the management plans and to identify the optimal setting for selecting candidate for surgery in suspicious recurrent ovarian cancer. Results. After PET scanning, the management plan was changed on 52 of 89 occasions (58.4%). The total number of cytoreductive surgeries selected as a treatment choice increased from 12 to 35. Miliary disseminated disease, which was not detected by PET scan, was found in 22.2% of surgeries. Miliary disseminated disease was detected in 6 of the 12 recurrent cases whose treatment-free interval (TFI) <12 months, whereas none of those with a TFI ≥12 months had such disease (p=0.0031). MethodsConclusions. PET or PET-CT is useful for selecting cytoreductive surgery candidates among patients with recurrent ovarian cancer. To avoid surgical attempts at miliary dissemination, patients with TFI ≥12 months are the best cytoreducive surgery candidates.

show abstract

Section: Discussionmentioning

confidence: 93%

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

Ebina

Watari

Kaneuchi

et al. 2013

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…These laparotomies are typically performed 6 months to 2 years after treatment, at which point, persistent disease, if present, has progressed to the point that is readily evident to the surgeon and the possibility of an earlier intervention has been precluded. Non-invasive diagnostic techniques, such as CA125 levels, ultrasound, computerised tomography, magnetic resonance imaging (MRI), and positron emission tomography (PET), which could in principle provide the benefit of more timely feedback, have all been shown to be less sensitive than reassessment surgeries (Pectasides et al, 1991;Sugiyama et al, 1996;Selman and Copeland, 1999;Morrow, 2000;Rose et al, 2001;Tammela and Lele, 2004). Hence, there is a vital un-met need for a new minimally invasive imaging approach with sufficient sensitivity and resolution to detect sub-millimetre OvCa nodules early in the treatment cycle, thus providing the basis for more timely interventions to mitigate recurrent disease.…”

mentioning

confidence: 99%

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: In patients with advanced ovarian cancer (OvCa), microscopic residual tumour nodules that remain after surgical debulking frequently escape detection by current treatment assessment methods and lead to disease recurrence. The aim of this study was to evaluate the use of high-resolution fibre-optic fluorescence imaging of the clinically approved photodynamic therapy (PDT) agent benzoporphyin-derivative monoacid ring A (BPD-MA) for detection of microscopic OvCa and for monitoring treatment response. METHODS: Our fluorescence microendoscope consists of a flexible imaging fibre coupled to a custom epi-fluorescence system optimised for imaging BPD-MA, which, after a single administration, serves as both an imaging agent and a light-activated therapeutic agent. After characterisation in an in vitro OvCa 3D model, we used the flexible imaging fibre to minimally invasively image the peritoneal cavity of a disseminated OvCa murine model using BPD-MA administered intraperitoneally (i.p.). To evaluate longitudinal changes in response to treatment, we compared sets of images obtained before and after PDT with those from untreated mice imaged at the same time points. RESULTS: By comparison with histopathology, we report an 86% sensitivity for tumour detection in vivo using the microendoscope. Using a custom routine to batch process-image data in the monitoring study, treated mice exhibited an average decrease of 58.8% in tumour volumes compared with an increase of 59.3% in untreated controls (Po0.05). CONCLUSIONS: Our findings indicate the potential of this approach as a reporter of treatment outcome that could aid in the rational design of strategies to mitigate recurrent OvCa.

show abstract

“…In contrast to CT and MRI, 18 F-FDG PET lymph node metastases determination was made based on physiological, rather than morphological characteristics (i.e., glucose turnover in a malignant cell). However, PET can also lead to false negative results for small-sized tumors (16).…”

Section: Discussionmentioning

confidence: 99%

Comparison of CT or MRI and₁₈F-FDG PET/CT for the Preoperative Staging Accuracy of Ovarian Cancer

Jung

Lee

et al. 2009

J Korean Soc Radiol

View full text Add to dashboard Cite

Ovarian cancer has the highest mortality rate of all gynecologic malignant tumors. An exploratory laparotomy is performed when a pelvic tumor is suspected of being malignant. The tumor stage is determined after an exploratory laparatomy and a thorough evaluation of all the specific lesions at risk in accordance with the recommendations of the International Federation of Gynecology and Obstetrics (FIGO) (1).Computed tomography (CT), Magnetic resonance imaging (MRI), and positron Emission Tomography (PET) have also been investigated as supplementary diagnostic tools for ovarian cancer. The accuracy of CT in

show abstract

Positive Emission Tomography for Evaluating a Complete Clinical Response in Patients with Ovarian or Peritoneal Carcinoma: Correlation with Second-Look Laparotomy

Cited by 122 publications

References 25 publications

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring

Comparison of CT or MRI and₁₈F-FDG PET/CT for the Preoperative Staging Accuracy of Ovarian Cancer

Contact Info

Product

Resources

About

Positive Emission Tomography for Evaluating a Complete Clinical Response in Patients with Ovarian or Peritoneal Carcinoma: Correlation with Second-Look Laparotomy

Cited by 122 publications

References 25 publications

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring

Comparison of CT or MRI and18F-FDG PET/CT for the Preoperative Staging Accuracy of Ovarian Cancer

Contact Info

Product

Resources

About

Comparison of CT or MRI and₁₈F-FDG PET/CT for the Preoperative Staging Accuracy of Ovarian Cancer